Suprafenacine, an Indazole-Hydrazide Agent, Targets Cancer Cells Through Microtubule Destabilization
作者:Bo-Hwa Choi、Souvik Chattopadhaya、Le Nguyen Thanh、Lin Feng、Quoc Toan Nguyen、Chuan Bian Lim、Amaravadhi Harikishore、Ravi Prakash Reddy Nanga、Nagakumar Bharatham、Yan Zhao、Xuewei Liu、Ho Sup Yoon
DOI:10.1371/journal.pone.0110955
日期:——
Microtubules are a highly validated target in cancer therapy. However, the clinical development of tubulin binding agents (TBA) has been hampered by toxicity and chemoresistance issues and has necessitated the search for new TBAs. Here, we report the identification of a novel cell permeable, tubulin-destabilizing molecule - 4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid [1p-tolyl-meth-(E)-ylidene]-hydrazide (termed as Suprafenacine, SRF). SRF, identified by in silico screening of annotated chemical libraries, was shown to bind microtubules at the colchicine-binding site and inhibit polymerization. This led to G2/M cell cycle arrest and cell death via a mitochondria-mediated apoptotic pathway. Cell death was preceded by loss of mitochondrial membrane potential, JNK - mediated phosphorylation of Bcl-2 and Bad, and activation of caspase-3. Intriguingly, SRF was found to selectively inhibit cancer cell proliferation and was effective against drug-resistant cancer cells by virtue of its ability to bypass the multidrug resistance transporter P-glycoprotein. Taken together, our results suggest that SRF has potential as a chemotherapeutic agent for cancer treatment and provides an alternate scaffold for the development of improved anti-cancer agents.
微管是抗癌疗法中经过充分验证的目标。然而,微管结合剂(TBA)的临床开发一直受到毒性和化疗抗性问题的阻碍,因此有必要寻找新的TBA。在此,我们报告了一种新型细胞通透性、微管不稳定性分子的鉴定——4,5,6,7-四氢-1H-吲唑-3-羧酸[1-甲苯基-甲-(E)-亚基]-酰肼(命名为Suprafenacine,SRF)。SRF是通过对注释化学库的计算机筛选鉴定的,它被证明在秋水仙素结合位点与微管结合并抑制聚合。这导致G2/M细胞周期阻滞和通过线粒体介导的凋亡途径的细胞死亡。细胞死亡之前是线粒体膜电位的丧失,JNK介导的Bcl-2和Bad的磷酸化,以及caspase-3的激活。有趣的是,SRF被发现能选择性抑制癌细胞增殖,并通过其绕过多药耐药转运蛋白P-糖蛋白的能力对耐药癌细胞有效。总的来说,我们的结果表明SRF具有作为抗癌化疗药物的潜力,并为开发改进的抗癌药物提供了另一种支架结构。